CRISPR Therapeutics to Participate in Upcoming Investor Conferences
November 21 2018 - 7:00AM
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company
focused on creating transformative gene-based medicines for serious
diseases, today announced that Samarth Kulkarni, Ph.D., Chief
Executive Officer of CRISPR Therapeutics, is scheduled to
participate in the following investor conferences in November:
30th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 28, 2018 Fireside Chat: 10:30 AM ET
Location: New York, NY
Barclays Gene Editing & Gene Therapy Summit
Date: Thursday, November 29, 2018 Presentation: 4:00 PM ETPanel
Discussion: 4:30 PM ET Focus on Gene Editing Location: New York,
NY
A live webcast of the Piper Jaffray fireside
chat will be available on the "Events & Presentations" page in
the Investors section of the Company's website
at https://crisprtx.com/events. A replay of the webcast will
be archived on the Company's website for 14 days following the
presentation.
About CRISPR TherapeuticsCRISPR
Therapeutics is a leading gene editing company focused on
developing transformative gene-based medicines for serious diseases
using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a
revolutionary gene editing technology that allows for precise,
directed changes to genomic DNA. CRISPR Therapeutics has
established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology,
regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic
collaborations with leading companies including Bayer AG, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is
headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based
in Cambridge, Massachusetts, and business offices in London, United
Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Investor Contact:Susan
Kimsusan.kim@crisprtx.com
CRISPR Media Contact:Jennifer PaganelliWCG on
behalf of CRISPR347-658-8290jpaganelli@wcgworld.com
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Mar 2024 to Apr 2024
CRISPR Therapeutics (NASDAQ:CRSP)
Historical Stock Chart
From Apr 2023 to Apr 2024